Head-to-head evidence
Inbrija (CVT-301) vs Levodopa-carbidopa intestinal gel
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
Inbrija (CVT-301)
Marketed by Merz Therapeutics
NCT02240030 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 351 participants and a clinical primary endpoint based on the UPDRS Part III motor score. Although the primary score numerically favored high-dose CVT-301 over placebo, the registry does not state whether that primary comparison was statistically significant, so the result remains unclear.
Levodopa-carbidopa intestinal gel · Duopa
Marketed by AbbVie
NCT00335153 · Phase 3 · completed
This was a 354-participant, open-label, single-group study with no randomization, blinding, or comparator arm. Its primary outcomes focused on safety and device complications, and there was no formal controlled primary efficacy comparison, so the reported secondary improvements do not establish treatment efficacy.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Inbrija (CVT-301)'s landscape · Levodopa-carbidopa intestinal gel's landscape